Pulmatrix Revenue 2014-2022 | PULM

Pulmatrix revenue from 2014 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Pulmatrix Annual Revenue
(Millions of US $)
2021 $5
2020 $13
2019 $8
2018 $0
2017 $0
2016 $1
2015 $1
2014 $0
2014 $
2013 $
2013 $
2012 $
Pulmatrix Quarterly Revenue
(Millions of US $)
2022-09-30 $2
2022-06-30 $1
2022-03-31 $1
2021-12-31 $0
2021-09-30 $1
2021-06-30 $2
2021-03-31 $1
2020-12-31 $2
2020-09-30 $4
2020-06-30 $4
2020-03-31 $3
2019-12-31 $2
2019-09-30 $1
2019-06-30 $5
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31 $0
2017-12-31
2017-09-30 $0
2017-06-30
2017-03-31
2016-12-31 $0
2016-09-30 $0
2016-06-30 $0
2016-03-31 $0
2015-12-31 $0
2015-09-30 $1
2015-06-30 $0
2015-03-31 $0
2014-12-31
2014-09-30 $0
2014-06-30
2014-03-31
2013-12-31
2013-09-30
2013-06-30
2013-03-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.015B $0.005B
Pulmatrix, Inc. is a biopharmaceutical company which is engaged in developing inhaled therapies for serious pulmonary disease. The Company's proprietary product pipeline includes PUR1900, an inhaled anti-fungal for cystic fibrosis, PUR0200, a branded generic for chronic obstructive pulmonary disease which are in different clinical stage. Its technology platform consists of iSPERSE. Pulmatrix, Inc., formerly known as Ruthigen, Inc., is based in Lexington, MA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $155.188B 9.47
GSK (GSK) United Kingdom $72.345B 9.01
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.333B 19.34
Ginkgo Bioworks Holdings (DNA) United States $3.395B 0.00
Myovant Sciences (MYOV) United Kingdom $2.604B 0.00
Arcus Biosciences (RCUS) United States $1.672B 25.10
Biohaven (BHVN) United States $1.264B 0.00
Emergent Biosolutions (EBS) United States $0.655B 5.15
ADC Therapeutics SA (ADCT) Switzerland $0.363B 0.00
Ambrx Biopharma (AMAM) United States $0.073B 0.00
Enzo Biochem (ENZ) United States $0.073B 0.00
Gelesis Holdings (GLS) United States $0.027B 0.00
SQZ Biotechnologies (SQZ) United States $0.025B 0.00